[
{
	"page":"ENAS5097_1.0.0.0",
	"text":"1.0.0.0 Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth De Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Parker C, Gillessen S, Heidenreich A and Horwich A, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(Suppl 5):v69–77 https://​academic.oup.com/​annonc/​article-pdf/​26/​suppl_5/​v69/​6675354/​mdv222.pdf Prostate cancer: eUpdate published online September 2016 ESMO Guidelines Committee Ann Oncol 2016;27(Suppl 5): v146–7 https://​academic.oup.com/​annonc/​article-​pdf/​27/​suppl_5/​v146/​1741730/​mdw361.pdf Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M and Horwich A, on behalf of the ESMO Guidelines Working Group Ann Oncol 2014;25(Suppl 3):iii40–8 https://​academic.oup.com/​annonc/​article-​pdf/​25/​suppl_3/​iii40/​6675909/​mdu223.pdf Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Escudier B, Porta C, Schmidinger M, Rioux-‍‍Leclercq N, Bex A, Khoo V, Gruenvald V and Horwich A, on behalf of the ESMO Guidelines Committee Ann Oncol 2016;27(Suppl 5): v58–68 https://​academic.oup.com/​annonc/​article-​pdf/​27/​suppl_5/​v58/​6679145/​mdw328.pdf Renal cell carcinoma: MCBS eUpdate published online 10 April 2017 ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv143-4 https://​academic.oup.com/​annonc/​article-​pdf/​28/​suppl_4/​iv143/​3958160/​mdx239.pdf Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Van Poppel H, Watkin NA, Osanto S, Moonen L, Horwich A and Kataja V, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi115–24 https://​academic.oup.com/​annonc/​article-​pdf/​24/​suppl_6/​vi115/​6675572/​mdt286.pdf Testicular seminoma and non-‍seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll H-J, Bokemeyer C, Horwich A, Beyer J and Kataja V, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi125–32 https://​academic.oup.com/annonc/​article-​pdf/​24/​suppl_6/​vi125/​6676323/​mdt304.pdf Testicular seminoma and non-seminoma: eUpdate published online 29 June 2017 Oldenburg J and Horwich A, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv165–6 https://​academic.oup.com/​annonc/​article-​pdf/​28/​suppl_4/​iv165/​3958168/​mdx257.pdf ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPG) on the management of urogenital cancers (prostate cancer, bladder cancer, renal cell carcinoma, penile cancer and testicular seminoma and non-‍seminoma). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-‍‍up. The ESMO CPG on urogenital cancers are intended to provide you with a set of recommendations for the best standards of care for urogenital cancers, using evidence-‍‍based medicine. Implementation of ESMO CPG facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on evidence-‍‍based management of urogenital cancers. Please visit http://www.esmo.org or http:/‍/‍oncologypro.esmo.org to view the full guidelines."
},
{
	"page":"ENAS5097_2.0.0.0",
	"text":"Diagnosis In patients with a testicular mass, testicular sonography should be carried out The size and any structural alterations of the contralateral testis should be noted Diagnosis of a testicular germ cell tumour (TGCT) should be based on histology of the testicular mass, removed by radical orchiectomy performed through an inguinal incision or by testis-‍conserving surgery in experienced centres Frozen section analysis should be considered intra-‍operatively to accurately differentiate malignant from benign testicular lesions Histological diagnosis should be carried out prior to further treatment unless the clinical situation requires immediate chemotherapy Histology of germ cell tumour (GCT) should be reported according to the World Health Organization (WHO) classification, specifying: Tumour size Multiplicity Tumour extension (e.g. in rete testis or other tissue) pT category (according to the American Joint Committee on Cancer [AJCC]/‍Union for International Cancer Control [UICC] tumour node metastasis [TNM] staging classification [7th edition]) All histological components with corresponding percentages Presence or absence of vascular invasion and testicular intraepithelial neoplasia (TIN) Elevation of tumour markers, i.e. serum levels of α-‍fetoprotein (AFP) and/‍or human chorionic gonadotropin (HCG), support the diagnosis, and analyses should be carried out before and after surgery until normalisation, progression or plateau development, since this information is used for final staging In seminomas, the presence of syncytiotrophoblasts should be reported Increased copy numbers of iso-‍chromosome 12p are found in both TGCT and extragonadal germ cell tumours (EGGCT) and provide a pathognomonic test, which might be useful in challenging histological diagnoses, e.g. somatically transformed teratoma Biopsy of midline extragonadal tumours is mandatory, unless the patient is very sick and has high tumour markers. The biopsy should be preceded by testicular sonography to exclude a TGCT Biopsy of the contralateral testis to establish a diagnosis of TIN is not routinely indicated"
},
{
	"page":"ENAS5097_3.1.0.0",
	"text":"Staging Overview Post-‍orchiectomy staging and risk group categorisation should be performed according to the AJCC/‍UICC and the International Germ Cell Cancer Collaborative Group (IGCCCG), reflecting the extent of the disease based on clinical and radiological examinations and the results of serum tumour markers after orchiectomy, including serum lactate dehydrogenase (LDH) For stage I disease, different risk factors have been identified for seminoma and non-‍seminoma based on histological features in the primary tumour For metastatic disease, the IGCCCG has identified three prognostic groups: Good, intermediate and poor (see tables here) The IGCCCG have provided prognostic information for chemotherapy-‍treated metastatic disease For patients with non-‍seminoma, a good, intermediate or poor prognosis group is identified. Patients with seminoma are categorised as either good or intermediate prognosis (there is no poor prognosis group) However, not all patients with metastases receive chemotherapy (see tables here in treatment section)"
},
{
	"page":"ENAS5097_2017032733",
	"text":"Computed tomography (CT) scan of the abdomen and pelvis is mandatory Thoracic CT should be carried out in cases of non-‍seminoma, but can be omitted in seminoma patients without infradiaphragmatic metastases Magnetic resonance imaging (MRI) of the central nervous system (CNS) is indicated in advanced disease stages, particularly in cases of choriocarcinoma/‍high HCG, or in those with cerebral symptoms Positron emission tomography (PET) scanning does not contribute to initial staging"
},
{
	"page":"ENAS5097_2017032734",
	"text":"Tumour markers (AFP, HCG, LDH) should be determined before orchiectomy and followed until normalisation or lack of further decrease Serum levels of total testosterone, luteinising hormone (LH) and follicle-‍stimulating hormone (FSH) should be determined Semen analysis and sperm banking should be discussed with all patients"
},
{
	"page":"ENAS5097_3.2.0.0",
	"text":"POST-ORCHIECTOMY STAGING OF METASTATIC SEMINOMA AND NON SEMINOMA ACCORDING TO THE AJCC/UICC AND IGCCCG CLASSIFICATION - LDH (U/L) HCG (IU/L) AFP (ng/mL) SX Marker studies not available or not carried out Marker studies not available or not carried out Marker studies not available or not carried out S0 Normal Normal Normal S1 < 1.5 x ULN < 5000 < 1000 S2 < 1.5-10 x ULN 5000–50 000 1000–10 000 S3 > 10 x ULN > 50 000 > 10 000 AFP, alpha-foetoprotein; AJCC, American Joint Committee on Cancer; hCG, human chorionic gonadotropin; IGCCCG, International Germ Cell Cancer Collaborative Group; LDH, lactate dehydrogenase; UICC, Union for International Cancer Control; ULN, upper limit of normal"
},
{
	"page":"ENAS5097_2018031636",
	"text":"THE IGCCCG PROGNOSTIC CLASSIFICATION FOR METASTATIC GERM CELL CANCERS GOOD-PROGNOSIS GROUP Non-seminoma (56% of cases) All of the following criteria: 5-year PFS 89% 5-year survival 92% Testicular/retroperitoneal primary No non-pulmonary visceral metastases AFP < 1000 ng/mL hCG < 5000 IU/L (1000 ng/mL) LDH < 1.5 x ULN 5-year PFS 82% 5-year survival 86% Any primary site No non-pulmonary visceral metastases Normal AFP Any hCG Any LDH Non-seminoma (28% of cases) --- 5-year PFS 75% Testicular/retroperitoneal primary No non-pulmonary visceral metastases 5-year survival 80% And any of the following criteria: hCG 5000–50 000 IU/L or LDH 1.5–10 x ULN Seminoma (10% of cases) All of the following criteria: 5-year PFS 67% 5-year survival 72% Any primary site No non-pulmonary visceral metastases Normal AFP Any hCG Any LDH POOR-PROGNOSIS GROUP Non-seminoma (16% of cases) Any of the following criteria: 5-year PFS 41% 5-year survival 48% Mediastinal primary Non-pulmonary visceral metastases AFP > 10 000 ng/mL or hCG > 50 000 IU/L (10 000 ng/mL) or LDH > 10 x ULN Seminoma No patients classified as poor prognosis Pre-chemotherapy serum tumour markers should be assessed after orchiectomy and immediately prior to the administration of chemotherapy (same day). AFP, alpha-foetoprotein; hCG, human chorionic gonadotropin; IGCCCG, International Germ Cell Cancer Collaborative Group; LDH, lactate dehydrogenase; PFS, progression-free survival; ULN, upper limit of normal"
},
{
	"page":"ENAS5097_4.1.0.0",
	"text":"Treatment Overview Before any treatment, the patient should be informed of the potential treatment modalities, their acute and late toxicities and the overall outcome Recommended options for post-‍orchiectomy treatment of seminoma and non-‍seminoma are summarised in the corresponding sections below Chemotherapy regimens for the treatment of metastatic seminoma and non-‍seminoma are summarised in the table here 3–4 cycles of bleomycin/‍etoposide/‍cisplatin (BEP) represents the standard treatment of metastatic patients Chemotherapy cycles should be repeated every 3 weeks, independently of leukocyte count, although infection at day 22 warrants delay of chemotherapy until recovery Tumour markers should be assessed before the start of each chemotherapy cycle"
},
{
	"page":"ENAS5097_4.2.0.0",
	"text":"Chemotherapy regimens REGIMEN DOSE SCHEDULE BEP* Repeat cycles every 3 weeks Cisplatin 20 mg/m² Days 1–5 Etoposide 100 mg/m² Days 1–5 Bleomycin 30 mg Day 1, 8, 15 EP† Repeat cycles every 3 weeks Cisplatin 20 mg/m² Days 1–5 Etoposide 100 mg/m² Days 1–5 VIP/‍PEI‡ Repeat cycles every 3 weeks Cisplatin 20 mg/m² Days 1–5 Etoposide 75 mg/m² Days 1–5 Ifosfamide 1.2 g/m2 Days 1–5 TIP§ Repeat cycles every 3 weeks Paclitaxel 250 mg/m² Day 1 Cisplatin 25 mg/m² Days 2–5 Ifosfamide 1.5 g/m2 Days 2–5 VeIP|| Repeat cycles every 3 weeks Vinblastine 0.11 mg/kg Days 1 + 2 Ifosfamide 1.2 g/m² Days 1–5 Cisplatin 20 mg/m² Days 1–5 TI-CE¶     TI Cycles 1–2 every 2 weeks Paclitaxel 200 mg/m² Day 1 Ifosfamide 2.0 g/m2 Days 2–4 CE Cycles 3–5 every 3 weeks Carboplatin AUC 7 Days 1–3 Etoposide 400 mg/m² Days 1–3 CE# 2 cycles, may be preceded by VeIP Carboplatin 700 mg/m² Day 1 Etoposide 750 mg/m² Days 1–3 *3 cycles of BEP in IGCCCG good prognosis, 4 cycles in intermediate or poor prognosis patients †4 cycles of EP only in IGCCCG good prognosis patients in case of contraindications to bleomycin ‡4 cycles of VIP only in IGCCCG intermediate or poor prognosis patients in cases of contraindications to bleomycin as first-‍line chemotherapy; or as salvage chemotherapy (PEI is synonymous to VIP) §4 cycles of TIP, typically as conventional dose salvage chemotherapy ||4 cycles of VeIP, typically as conventional dose salvage chemotherapy ¶2 cycles of TI before stem cell harvesting and 3 cycles of CE thereafter as high-‍dose treatment #2 cycles of CE as high-‍dose treatment; may be preceded by cytoreductive VeIP AUC, area under the curve; BEP, bleomycin/etoposide/cisplatin; CE, carboplatin/‍etoposide; EP, etoposide/‍cisplatin; IGCCCG, InternationalGerm Cell Cancer Collaborative Group; TI, paclitaxel/‍ifosfamide; TIP, paclitaxel/‍ifosfamide/cisplatin; VeIP, vinblastine/‍ifosfamide/‍cisplatin; VIP/‍PEI, etoposide/‍ifosfamide/‍cisplatin;"
},
{
	"page":"ENAS5097_4.3.1.0",
	"text":"Seminoma Overview For Stage I disease, the cure rate is very high (~ 99%) and so minimising treatment-‍related toxicity is the priority Surveillance is the preferred strategy, if accepted by the patient Risk factors, such as rete testis infiltration and tumour size ≥ 4 cm, are sometimes used to apply one course of carboplatin or radiotherapy as adjuvant treatment For Stage IIA disease, treatment options consist of either cisplatin-‍based chemotherapy or radiotherapy to the para-‍aortic and ipsilateral iliac lymph nodes with 30 Gy in 2 Gy fractions Neoadjuvant carboplatin prior to radiotherapy may reduce relapse rates but this strategy requires further evaluation For Stage IIB/‍IIC disease, 3 cycles of BEP is the standard therapy If there are arguments against bleomycin, e.g. reduction in lung capacity, emphysema, heavy smoking (including former smokers) or poor renal function, 4 cycles of etoposide/‍cisplatin (EP) can be used Patients unsuitable for chemotherapy should receive radiotherapy to the para-‍aortic and ipsilateral iliac fields with 36 Gy in 2 Gy fractions For Stage III disease, chemotherapy with BEP is the standard treatment 3 cycles for good prognosis patients according to IGCCCG [or 4 cycles of EP if there are arguments against bleomycin] 4 cycles for intermediate prognosis patients according to IGCCCG [or 4 cycles of etoposide/‍ifosfamide/‍cisplatin (VIP/‍PEI) if there are arguments against bleomycin] Patients with a complete response following chemotherapy do not require further treatment In cases of residual tumour, a fluorodeoxyglucose positron emission tomography (FDG-‍PET) scan at least 6 weeks after ending chemotherapy may be carried out The recommended approach for lesions > 3 cm May be considered for lesions < 3 cm but the positive predictive value is lower, and surveillance is preferred If PET is unavailable, lesions > 3 cm can be biopsied, resected or followed until resolution/‍progression A negative PET scan warrants follow-‍up only For a positive PET scan, biopsy may be carried out before treatment with irradiation or resection. However, perioperative complications are more common than in non-‍seminoma due to desmoplastic reactions of the chemotherapy-exposed seminoma metastases"
},
{
	"page":"ENAS5097_4.3.2.0",
	"text":"Standard treatment strategies   STAGE I STAGE IIA STAGE IIB/‍IIC/‍III First line Low risk* Preferred: Surveillance Alternatively: Carboplatin x 1 (AUC 7) Radiotherapy (20 Gy) BEP x 3 (or EP x 4) Radiotherapy BEP x 3–4 (VIP x 3–4) High risk†     Preferred: Surveillance Carboplatin x 1 (AUC 7) Alternatively: Radiotherapy (20 Gy / 10 fractions to para-‍aortic target volume)     Residual disease n/a Observation Consider biopsy or resection of lesion > 3 cm, particularly if PET positive Relapse Post-‍surveillance/‍carboplatin: Localised: Radiotherapy Otherwise: BEP x 3–4 Post-‍radiotherapy: BEP x 3 (or EP x 4) Salvage chemotherapy In localised lesions: Consider radiotherapy Surgery in case of single resectable lesion *Low risk: Absence of rete testis invasion and tumour < 4 cm †High risk: Rete testis invasion or tumour ≥ 4 cm AUC, area under the curve; BEP, bleomycin/etoposide/cisplatin; EP, etoposide/cisplatin; PET, positron emission tomography; VIP, etoposide/ifosfamide/cisplatin"
},
{
	"page":"ENAS5097_4.4.1.0",
	"text":"Non-‍seminoma Overview Stage I non-‍seminoma is categorised according to the absence (low risk) or presence (high risk) of vascular invasion For low-‍risk Stage I disease, if surveillance is not feasible, 1–2 cycles of adjuvant chemotherapy with BEP may be given (usually 1 cycle) For patients unsuitable for surveillance or adjuvant chemotherapy, open nerve-‍sparing retroperitoneal lymph node dissection (RPLND) is an option in highly experienced centres For high-‍risk Stage I disease, surveillance or adjuvant chemotherapy (1–2 cycles of BEP) are recommended options Nerve-‍sparing RPLND may be carried out in case of contraindications to the above, and may be preferred by some experts for patients with teratoma and somatic transformation in the primary tumour For Stage IIA/‍IIB marker-‍negative disease, overtreatment might be avoided by the following strategies: Close follow-‍up with abdominal imaging every 6 weeks until regression or progression, resulting in observation only or treatment, respectively In case of a single progressing lymph node and the presence of normal markers suggestive of teratoma, treatment may consist of primary nerve-‍sparing RPLND or chemotherapy In case of multiple progressive lymph nodes and/‍or rising tumour markers suggestive of non-teratomatous TGCT, chemotherapy (3 cycles of BEP) is indicated Lymph node biopsy or primary nerve-‍sparing RPLND Adjuvant chemotherapy post-‍RPLND (2 cycles of BEP) may be considered in cases of vital GCT in the specimen Completely resected teratoma warrants follow-‍up only For Stage IS/‍II/‍III disease, chemotherapy with BEP is the standard treatment 3 cycles BEP should be administered for good prognosis patients If there are arguments against bleomycin, 4 cycles of EP can be used 4 cycles BEP should be administered for intermediate or poor prognosis patients (BEP can be substituted with VIP if there are arguments against bleomycin) Poor prognosis patients with insufficient tumour marker decline after the first cycle of BEP might benefit from dose intensification of first-‍line therapy rather than continuation of standard BEP treatment, although evidence for an optimal dose-‍dense regimen is still needed For Stage IIA/‍IIB marker-‍positive disease, 3 cycles of BEP is recommended If there are arguments against bleomycin, 4 cycles of EP can be used Assessment of tumour markers and imaging (chest X-ray, CT/‍MRI of the initial sites) should be carried out 4–8 weeks after the last chemotherapy cycle In case of complete response, no further treatment is necessary Residual lymph nodes > 10 mm in diameter should be removed by open nerve-‍sparing RPLND Any residual tumour with normal markers should be resected if technically feasible, although cases of multiple visceral metastases should be discussed with experts and treated at specialised centres Patients with residual lesions that are deemed resectable and those with plateauing tumour markers should undergo immediate surgery by experienced surgeons Patients with elevated tumour markers should receive individualised treatment based on recommendations by experts Elevated tumour markers should be assessed at least once weekly Rising tumour markers indicate progressive GCT, usually requiring highly specialised multi-‍disciplinary therapy (see salvage treatment here ) A laparoscopic RPLND should only be carried out in clinical trials Patients with a good prognosis and completely resected viable malignant tumour comprising < 10% of the specimen do not benefit from adjuvant chemotherapy. However, patients with intermediate or poor prognosis and > 10% viable tumour in the specimen and/‍or incomplete resection may benefit from consolidation chemotherapy, e.g. 2 cycles of VIP, although a surveillance strategy is also justified"
},
{
	"page":"ENAS5097_4.4.2.0",
	"text":"Standard treatment strategies STAGE I STAGE II∕III GOOD INTERMEDIATE POOR First line Vascular invasion absent Preferred: Surveillance Alternatively: BEP x 1–2 RPLND (rarely) Vascular invasion present Preferred: BEP x 1–2 Surveillance Alternatively: RPLND (rarely)   BEP x 3 (or EP x 4) RPLND (if marker negative Stage IIA)   BEP x 4 VIP x 4   BEP x 4 VIP x 4 Residual disease n/a Resection in case of lesion > 1 cm Observation in case of lesion < 1 cm Relapse Post-‍surveillance or post-‍RPLND: BEP x 3–4 Surgery in case of single resectable lesion Post-‍chemotherapy: Salvage chemotherapy   Surgery in case of single resectable lesion Salvage chemotherapy Surgery in case of single resectable lesion BEP, bleomycin/etoposide/cisplatin; EP, etoposide/cisplatin; RPLND, retroperitoneal lymph node dissection; VIP, etoposide/ifosfamide/cisplatin"
},
{
	"page":"ENAS5097_4.5.1.0",
	"text":"Salvage treatment Overview The prognosis of relapsing GCT patients is variable, as shown by the International Prognostic Factor Study Group (see table here) No salvage treatment recommendations can be made for patients who have relapsed after cisplatin-‍based first-‍line chemotherapy In refractory patients, i.e. those not reaching a marker-‍negative complete response after first-‍line treatment or those without a favourable response to salvage treatment, further treatment must be individualised by GCT experts These patients should be included in clinical trials, if available Surgery should be part of the strategy whenever possible, particularly in patients with localised or late relapse, and those with a poor response to chemotherapy"
},
{
	"page":"ENAS5097_4.5.2.0",
	"text":"Primary site? Max.3.0 Gonadal"
},
{
	"page":"ENAS5097_4.6.0.0",
	"text":"Late relapse Patients with late relapse, defined as new tumour growth > 2 years after ≥ 3 cycles of chemotherapy, do not respond well to further chemotherapy For marker-‍negative relapses, histological assessment of the relapsing lesions should be carried out by radical surgical resection of all lesions, if technically feasible Further chemotherapy must be individualised based on histology of the late relapse and tumour marker development If salvage chemotherapy is the first treatment option of a late relapse, radical post-‍chemotherapy surgery should be conducted whenever possible"
},
{
	"page":"ENAS5097_4.7.0.0",
	"text":"Late toxicity Determination of testosterone levels is recommended during follow-‍up in order to detect hypogonadism, although it is not clear when and at what level testosterone replacement therapy should be offered Patients should be counselled on a healthy lifestyle (no smoking, regular physical exercise) in order to minimise the risk for late post-‍chemotherapy cardiovascular disease and metabolic syndrome Patients should also be screened for other known risk factors such as hypertension, dyslipidaemia and excessive weight gain Further dose-‍related late sequelae include pulmonary and renal toxicity, ototoxicity and neurotoxicity, which should be monitored as part of patient follow-‍up, as needed"
},
{
	"page":"ENAS5097_5.0.0.0",
	"text":"Personalised medicine More research is needed to identify molecular markers that could lead to advances in personalised medicine"
},
{
	"page":"ENAS5097_6.0.0.0",
	"text":"Follow-‍up and surveillance Follow-‍up schedule recommendations should be adapted according to national and institutional requirements Many follow-‍up recommendations that have been published most likely expose TGCT survivors to unnecessary radiation, increasing the risk of a radiation-induced second cancer Replacing CT by MRI scan would reduce this risk, but is not feasible for the majority of European countries. Nevertheless, effort should be made to reduce the frequency of CT scans and limit their overall number PET-‍CT scanning has no role in the routine follow-‍up of TGCT patients"
},
{
	"page":"ENAS5097_7.1.0.0",
	"text":"Summary of recommendations Diagnosis Patients with a testicular mass should undergo testicular sonography Diagnosis of TGCC should be based on histology of the testicular mass, removed by radical orchiectomy or testis-‍conserving surgery Histological diagnosis should be carried out prior to further treatment unless the clinical situation requires immediate chemotherapy Histology report should include: Tumour size, multiplicity, tumour extension (e.g. in rete testis or other tissue), pT category, all histological components with corresponding percentages, presence/‍absence of vascular invasion and TIN Tumour marker assessments support a diagnosis and are useful for staging Biopsy of midline extragonadal tumours is mandatory, unless the patient is very sick and has high tumour markers"
},
{
	"page":"ENAS5097_7.2.0.0",
	"text":"Staging Post-‍orchiectomy staging and risk group categorisation should be performed according to the AJCC/‍UICC and the IGCCCG Imaging should include: CT of the abdomen and pelvis, thoracic CT (non-‍seminoma or seminoma without infradiaphragmatic metastases), MRI of the CNS for advanced disease Blood tests should include: Tumour markers (AFP, HCG, LDH), serum levels of total testosterone, LH and FSH Semen analysis and sperm banking should be discussed with all patients The IGCCCG has identified three prognostic groups for patients with metastatic disease: Good, intermediate and poor"
},
{
	"page":"ENAS5097_7.3.1.0",
	"text":"Treatment Seminoma Stage I: Surveillance is preferred (one course of carboplatin or radiotherapy as adjuvant treatment may be added) Stage IIA: Options are cisplatin-‍based chemotherapy or radiotherapy to the para-‍aortic and ipsilateral iliac lymph nodes (30 Gy in 2 Gy fractions) Stage IIB/‍IIC: 3 cycles of BEP is standard (or 4 cycles of EP or radiotherapy to the para-‍aortic and ipsilateral iliac fields [36 Gy in 2 Gy fractions]) Stage III: BEP is standard (3 cycles for good prognosis [or 4 cycles of EP], 4 cycles for intermediate prognosis [or 4 cycles of VIP])"
},
{
	"page":"ENAS5097_7.3.2.0",
	"text":"Non-‍seminoma Low-‍risk stage I: Surveillance is preferred (1–2 cycles of adjuvant BEP or nerve-‍sparing RPLND are alternatives if surveillance is not feasible/‍appropriate) High-‍risk stage I: Surveillance or 1–2 cycles of adjuvant BEP are options (nerve-‍sparing RPLND is an alternative and may be preferred for patients with teratoma and somatic transformation in the primary tumour) Stage IIA/‍IIB marker-‍negative: Options include close follow-‍up with abdominal imaging every 6 weeks until regression or progression, resulting in observation only or treatment (e.g. nerve-‍sparing RPLND or chemotherapy), respectively; or lymph node biopsy or primary nerve-‍sparing RPLND Stage IIA/‍IIB marker-‍positive: 3 cycles of BEP is preferred (4 cycles of EP is an alternative) Stage IS/‍II/‍III: BEP is standard (3 cycles for good prognosis patients, 4 cycles for intermediate or poor prognosis patients [or 4 cycles of VIP]). Poor prognosis patients may benefit from dose intensification if there is insufficient tumour marker decline after the first cycle of BEP"
},
{
	"page":"ENAS5097_7.3.3.0",
	"text":"Metastatic seminoma and non-‍seminoma Chemotherapy regimens include: BEP, EP, VIP/‍PEI, TIP, VeIP, TI-CE 3–4 cycles of BEP is considered standard Chemotherapy cycles should be repeated every 3 weeks, independently of leukocyte count, although infection at day 22 warrants delay of chemotherapy until recovery Tumour markers should be assessed before the start of each chemotherapy cycle"
},
{
	"page":"ENAS5097_7.3.4.0",
	"text":"Salvage treatment No salvage treatment recommendations can be made for patients who have relapsed after cisplatin-‍based first-‍line chemotherapy In refractory patients, further treatment must be individualised by GCT experts. These patients should be included in clinical trials, if available"
},
{
	"page":"ENAS5097_7.3.5.0",
	"text":"Late relapse and toxicity Patients with late relapse do not respond well to further chemotherapy For marker-‍negative relapses, histological assessment of relapsing lesions should be carried out by radical surgical resection of all lesions, if feasible If salvage chemotherapy is the first treatment option of a late relapse, radical post-‍chemotherapy surgery should be conducted, if possible Late toxicity may include hypogonadism, cardiovascular disease, metabolic syndrome, pulmonary and renal toxicity, ototoxicity and neurological sequelae, which should be monitored as part of patient follow-‍up, as needed. Patients should be counselled on a healthy lifestyle and screened for any additional risk factors (e.g. hypertension, dyslipidaemia, excessive weight gain)"
},
{
	"page":"ENAS5097_7.4.0.0",
	"text":"Follow-‍up Follow-‍up schedules should be adapted according to national and institutional requirements Many published follow-‍up schedules are likely to expose TGCT survivors to unnecessary radiation – replacing CT with MRI reduces this risk. If unfeasible, the number and frequency of CT scans should be reduced"
},
{
	"page":"ENAS5097_8.0.0.0",
	"text":"Glossary 18FDG-‍PET 18Fluorodeoxyglucose-‍‍positron emission tomography 5-FU 5-‍fluorouracil ADT androgen deprivation therapy AFP α-‍fetoprotein AJCC American Joint Committee on Cancer AML angiomyolipoma AUC area under the curve BCG Bacille Calmette-‍‍Guerin BD Bowen’s disease BEP bleomycin/‍‍etoposide/‍cisplatin BP Bowenoid papulosis BSC best supportive care CA cryoablation CarboGem carboplatin/‍‍gemcitabine ccRCC clear cell renal cell carcinoma CDKN2A cyclin-‍‍dependent kinase inhibitor 2A CE carboplatin/‍etoposide CHMP Committee for Medicinal Products for Human Use ChT chemotherapy CIS carcinoma in situ CNS central nervous system CO2 carbon dioxide CPG Clinical Practice Guidelines CR complete remission CRP C-‍reactive protein CRPC castration-‍‍resistant prostate cancer CSS cancer-specific survival CT computed tomography DFS disease-‍‍free survival DRE digital rectal examination DSNB dynamic sentinel node biopsy EAU European Association of Urology EBRT external beam radiotherapy ECOG Eastern Cooperative Oncology Group EGGCT extragonadal germ cell tumour EP etoposide/‍cisplatin EQ erythroplasia of Queyrat ESMO European Society for Medical Oncology FAT FRAP-‍ATM-‍TTRAP FDA Food and Drug Administration FDG-‍PET 18Fluorodeoxyglucose positron emission tomography FGF fibroblast growth factor FNA fine needle aspiration FNAC fine-‍needle aspiration cytology FSH follicle-‍‍stimulating hormone GC gemcitabine/‍cisplatin GCT germ cell tumour GS Gleason Score HCG human chorionic gonadotropin HDMVAC high-‍dose intensity methotrexate/‍‍vinblastine/‍‍doxorubicin/‍‍‍cisplatin HT hormonal therapy IFN interferon IGCCCG International Germ Cell Cancer Collaborative Group IL interleukin ILND inguinal lymph node dissection IMDC International Metastatic RCC Database Consortium IPOMC immediate postoperative mitomycin C Ir iridium ISUP International Society of Urological Pathology IV intravenous LDH lactate dehydrogenase LH luteinising hormone LN lymph node LND lymph node dissection M-‍CAVI methotrexate/‍‍carboplatin/‍‍vinblastine MDT multidisciplinary team MIBC muscle-‍‍invasive bladder cancer MRI magnetic resonance imaging MSKCC Memorial Sloane Kettering Cancer Center mTOR mammalian target of rapamycin MVAC methotrexate/‍‍vinblastine/‍‍doxorubicin/‍‍‍cisplatin Nd:YAG neodymium yttrium aluminium garnet NMIBC non-muscle-‍‍invasive bladder cancer NRF2-ARE nuclear factor erythroid 2-‍related factor 2-‍antioxidant responsive element OS overall survival PC prostate cancer PCG paclitaxel/‍‍carboplatin/‍‍‍gemcitabine PD progressive disease PD-1 programmed death 1 PEI ifosfamide/‍‍etoposide/‍‍cisplatin PET positron emission tomography PFI progression-‍‍free interval PFS progression-‍‍free survival PLND pelvic lymph node dissection PN partial nephrectomy PRm partial remission PS performance status PSA prostate specific antigen RC radical cystectomy RCC renal cell carcinoma RECIST Response Evaluation Criteria in Solid Tumors RFA radiofrequency ablation RN radical nephrectomy RP radical prostatectomy RPLND retroperitoneal lymph node dissection RT radiotherapy SBRT stereotactic body radiotherapy SCC squamous cell carcinoma SD stable disease SDH succinate dehydrogenase SRE skeletal-‍‍related event SRS stereotactic radiosurgery SSIGN stage, size, grade and necrosis TGCT testicular germ cell tumour TI paclitaxel/‍‍ifosfamide TIN testicular intraepithelial neoplasia TIP paclitaxel/‍‍ifosfamide/‍‍cisplatin Tis carcinoma in situ TKI tyrosine kinase inhibitor TNM tumour node metastasis TRUS transrectal ultrasound TUR transurethral resection TURBT transurethral resection of the bladder tumour UICC Union for International Cancer Control UISS University of California, Los Angeles (UCLA) Integrated Staging System ULN upper limit of normal US ultrasound VEGF vascular endothelial growth factor VeIP vinblastine/‍‍ifosfamide/‍‍‍cisplatin VHL Von Hippel-‍‍Lindau VIP etoposide/ifosfamide/‍‍cisplatin VMAT volumetric modulated arc therapy WBRT whole brain radiotherapy WHO World Health Organization .TFtable{ width: 100%; table-‍layout: auto; border-‍collapse: collapse; margin: 5px 0px 5px 1px; } .TFtable tr{ background: #b8d1f3; padding: 2px 2px 2px 2px; } .TFtable tr:nth-‍child(odd){ background-‍color: #CCC; font-‍weight: normal; text-‍align: left; vertical-‍align: middle; padding: 2px 2px 2px 2px; } .TFtable tr:nth-‍child(even){ background: #ffffff; padding: 2px 2px 2px 2px; }"
}
]